DURHAM, N.C. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing enterprise, has revealed compelling preclinical data today that supports the advancement of its innovative therapeutic candidate, PBGENE-HBV, towards clinical development. The company plans to initiate its first-in-human clinical trial, dubbed ELIMINATE-B, aimed at treating patients suffering from chronic hepatitis B.
Utilising its proprietary ARCUS platform, Precision BioSciences is at the forefront of developing in vivo gene editing therapies designed to achieve precise genomic modifications. The ARCUS technology offers a novel approach to gene editing, and the promising results from preclinical experiments provide a solid foundation for the upcoming clinical trials.
During the presentation, company executives highlighted the scientific rationale behind PBGENE-HBV, focusing on its potential to address the unmet medical needs of patients with chronic hepatitis B, a condition that affects millions worldwide. The ELIMINATE-B trial is designed to evaluate the safety, tolerability, and efficacy of PBGENE-HBV, with the aim of providing a transformative treatment option for those afflicted by this persistent viral infection.
The announcement marks a significant milestone in Precision BioSciences mission to pioneer cutting-edge gene therapies. As the company prepares for the clinical study, stakeholders remain optimistic about the potential breakthrough that PBGENE-HBV may represent in the field of hepatology and gene therapy.
Precision BioSciences is anticipated to share further details about the trial protocol and patient eligibility criteria in the coming weeks as it gears up for the first patient dosing, a pivotal step towards realising the therapeutic potential of this promising candidate.
(End of )
Comments